Personalis, Inc. (PSNL)Healthcare | Diagnostics & Research | Fremont, United States | NasdaqGM
17.07 USD
+0.27
(1.607%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 17.35 +0.28 (1.630%) ⇧ (Aug. 28, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:38 a.m. EDT
The immediate outlook is driven by a massive corporate event: the proposed acquisition by Tempus AI. This deal transforms the investment thesis from a standalone biotech gamble to a potential strategic pivot, which explains the recent price momentum and the heavy call buying at higher strikes. However, the long-term picture remains deeply troubled. The company has suffered a catastrophic multi-year decline, dropping nearly 75% over six years, with four of the last five years seeing negative returns. Fundamentals are broken, with negative earnings, negative free cash flow, and a return on equity of -50%. While the acquisition talks provide a temporary catalyst, the underlying business has failed to generate value for years. The lack of any dividend history confirms this is purely a speculative vehicle. Investors should view the current price as a reaction to the merger rumor, not a sign of a recovered business. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.111327 |
| MSTL | 0.166161 |
| AutoETS | 0.179898 |
| AutoARIMA | 0.462926 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 0.43 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.113 |
| Excess Kurtosis | -1.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 16.157 |
| Revenue per Share | 0.713 |
| Market Cap | 1,822,237,440 |
| Forward P/E | -18.13 |
| Beta | 2.29 |
| Profit Margins | -153.84% |
| Website | https://www.personalis.com |
As of Aug. 22, 2026, 3:38 a.m. EDT: Speculators are positioning aggressively for upside despite the stock's recent rally. Call volume significantly exceeds open interest at strikes 20.0 and 25.0 for the September expiration, indicating new money betting on a continued surge. Conversely, put activity is concentrated entirely out-of-the-money, suggesting traders are hedging against a pullback rather than expecting a crash, though the lack of in-the-money put protection highlights the perceived fragility of the current price level.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.4927235 |
| Address1 | 6,600 Dumbarton Circle |
| All Time High | 53.46 |
| All Time Low | 0.891 |
| Ask | 17.35 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 2.2 - Buy |
| Average Daily Volume10 Day | 4,845,420 |
| Average Daily Volume3 Month | 4,201,688 |
| Average Volume | 4,201,688 |
| Average Volume10Days | 4,845,420 |
| Beta | 2.285 |
| Bid | 9.7 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 2.211 |
| City | Fremont |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 17.07 |
| Current Ratio | 5.283 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 17.2377 |
| Day Low | 16.6 |
| Debt To Equity | 16.157 |
| Display Name | Personalis |
| Earnings Call Timestamp End | 1,778,187,600 |
| Earnings Call Timestamp Start | 1,778,187,600 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,793,736,000 |
| Earnings Timestamp Start | 1,793,736,000 |
| Ebitda | -104,596,000 |
| Ebitda Margins | -1.5013299 |
| Enterprise To Ebitda | -15.76 |
| Enterprise To Revenue | 23.661 |
| Enterprise Value | 1,648,411,776 |
| Eps Current Year | -1.0925 |
| Eps Forward | -0.94143 |
| Eps Trailing Twelve Months | -1.09 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 752 1301 |
| Fifty Day Average | 13.7898 |
| Fifty Day Average Change | 3.2802 |
| Fifty Day Average Change Percent | 0.23787148 |
| Fifty Two Week Change Percent | 249.27234 |
| Fifty Two Week High | 18.89 |
| Fifty Two Week High Change | -1.8199997 |
| Fifty Two Week High Change Percent | -0.09634726 |
| Fifty Two Week Low | 4.671 |
| Fifty Two Week Low Change | 12.399 |
| Fifty Two Week Low Change Percent | 2.6544638 |
| Fifty Two Week Range | 4.671 - 18.89 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,561,037,400,000 |
| Float Shares | 72,332,349 |
| Forward Eps | -0.94143 |
| Forward P E | -18.13199 |
| Free Cashflow | -56,028,248 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 259 |
| Fullday Change | 0.27 |
| Fullday Change Percent | 1.60715 |
| Fullday Price | 17.3482 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.12686 |
| Gross Profits | 8,838,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.26148 |
| Held Percent Institutions | 0.66735 |
| Implied Shares Outstanding | 106,750,881 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California. |
| Long Name | Personalis, Inc. |
| Market | us_market |
| Market Cap | 1,822,237,440 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_139360745 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -107,179,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,790,499,854 |
| Number Of Analyst Opinions | 4 |
| Open | 16.65 |
| Operating Cashflow | -92,298,000 |
| Operating Margins | -1.50248 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 650 752 1300 |
| Post Market Change | 0.27820015 |
| Post Market Change Percent | 1.6297607 |
| Post Market Price | 17.3482 |
| Post Market Time | 1,787,961,561 |
| Previous Close | 16.8 |
| Price Eps Current Year | -15.624714 |
| Price Hint | 2 |
| Price To Book | 7.7204885 |
| Price To Sales Trailing12 Months | 26.155642 |
| Profit Margins | -1.5383999 |
| Quick Ratio | 4.91 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.2 |
| Region | US |
| Regular Market Change | 0.27 |
| Regular Market Change Percent | 1.60715 |
| Regular Market Day High | 17.2377 |
| Regular Market Day Low | 16.6 |
| Regular Market Day Range | 16.6 - 17.2377 |
| Regular Market Open | 16.65 |
| Regular Market Previous Close | 16.8 |
| Regular Market Price | 17.07 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 2,973,107 |
| Return On Assets | -0.25032 |
| Return On Equity | -0.5032 |
| Revenue Growth | 0.3 |
| Revenue Per Share | 0.713 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 106,750,881 |
| Shares Percent Shares Out | 0.078600004 |
| Shares Short | 8,398,426 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 11,097,287 |
| Short Name | Personalis, Inc. |
| Short Percent Of Float | 0.1228 |
| Short Ratio | 2.08 |
| Source Interval | 15 |
| State | CA |
| Symbol | PSNL |
| Target High Price | 16.25 |
| Target Low Price | 13.0 |
| Target Mean Price | 15.4375 |
| Target Median Price | 16.25 |
| Total Cash | 212,658,000 |
| Total Cash Per Share | 1.991 |
| Total Debt | 37,996,000 |
| Total Revenue | 69,669,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.09 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.6161 |
| Two Hundred Day Average Change | 7.4538994 |
| Two Hundred Day Average Change Percent | 0.77514786 |
| Type Disp | Equity |
| Volume | 2,973,107 |
| Website | https://www.personalis.com |
| Zip | 94,555 |